Detalhe da pesquisa
1.
Efficacy and safety of nivolumab combined with brentuximab vedotin after nivolumab monotherapy failure in patients with relapsed and refractory classic Hodgkin lymphoma.
Int J Clin Oncol
; 27(3): 626-632, 2022 Mar.
Artigo
Inglês
| MEDLINE | ID: mdl-34826011
2.
Mucormycosis in haematological patients: case report and results of prospective study in Saint Petersburg, Russia.
Mycoses
; 57 Suppl 3: 91-6, 2014 Dec.
Artigo
Inglês
| MEDLINE | ID: mdl-25187314
3.
Clinical Outcomes in Patients With COVID-19 and Hematologic Disease.
Clin Lymphoma Myeloma Leuk
; 23(8): 589-598, 2023 08.
Artigo
Inglês
| MEDLINE | ID: mdl-37236904
4.
A Study of Safety and Efficacy of Nivolumab and Bendamustine (NB) in Patients With Relapsed/Refractory Hodgkin Lymphoma After Nivolumab Monotherapy Failure.
Hemasphere
; 4(3): e401, 2020 Jun.
Artigo
Inglês
| MEDLINE | ID: mdl-32647803
5.
A Phase 2 Study of Nivolumab Using a Fixed Dose of 40âmg (Nivo40) in Patients With Relapsed/Refractory Hodgkin Lymphoma.
Hemasphere
; 4(5): e480, 2020 Oct.
Artigo
Inglês
| MEDLINE | ID: mdl-33062947